NovellusDx early detection test is a simple to perform blood test, which identifies the deregulated signaling pathways within the patient tumor based on protein secretion to the blood, thus enabling early stage disease signature detection. The investigators' current clinical trial is focused on proving the main feature of NovellusDx's Early Detection Test- discriminating between cancer patients and healthy subjects.
Study Type
OBSERVATIONAL
Enrollment
50
Rambam MC
Haifa, Israel
Number of Participants with a significant cancer fingerprint as measured by NovellusDX Cancer Early Detection test
NovellusDX Cancer Early Detection test will identify participants with significant cancer fingerprint based on tumor protein secretion to the blood circulation in sick subjects.
Time frame: 3.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.